$GDRX

GoodRx Holdings, Inc. (GDRX): Submission of Matters to a Vote of Security Holders

GoodRx Holdings, Inc. (GDRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. gdrx-20260616 0001809519 FALSE 2701 Olympic Boulevard Santa Monica California 0001809519 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURREN

Original reporting
Published Jun 18, 2026, 8:19 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$GDRX
Neutral
high confidence
Mentioned
$GDRX
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GDRXNeutralLow
01

Why it matters

The disclosure confirms the election of three Class III directors, ratification of KPMG LLP as independent auditor for FY ending Dec. 31, 2026, and advisory approval of executive compensation; it does not provide new guidance or material corporate actions.

02

Market read

This is a governance/meeting recap rather than a catalyst; traders typically treat it as low-signal unless tied to a contested vote or strategic change (not present here).

03

What to watch

The filing includes voting power details (Class A vs Class B) that may matter for longer-term control dynamics, but it does not signal a change in strategy or risk.

Relevance 6/10Novelty 2/10Timing: post-close/after-hours filing of June 16 annual meeting vote results

Background

The company submitted an SEC Form 8-K (Item 5.07) summarizing matters voted on at its June 16, 2026 annual meeting.

Company-level read

Ticker impact

$GDRXNeutralHigh confidence
Context

GoodRx filed an 8-K reporting final voting results from its June 16, 2026 annual meeting, including director elections and auditor ratification.

Expected impact

Limited near-term impact; any reaction is likely muted and short-lived.

Evidence & confidence

The filing is a standard Item 5.07 disclosure of votes (directors, KPMG ratification, advisory comp approval) without new operating or financial datapoints.

Market effects

Minimal; governance vote outcomes typically do not change sector fundamentals for digital health/pharmacy benefit platforms.

None indicated.

None indicated.

Counterpoint

If investors were concerned about governance or auditor continuity, the ratification and director slate could reduce uncertainty, but the filing still lacks new fundamentals.

Key entities

  • GoodRx Holdings, Inc.

    Nasdaq-listed company filing Item 5.07 8-K with final shareholder voting results.

  • KPMG LLP

    Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

  • Wendy Barnes / Ronald E. Bruehlman / Gregory Mondre

    Elected as Class III directors for terms expiring at the 2029 annual meeting.

Related articles

$OSCRMed

GoodRx and Oscar Health Tout Tech as Consumer Needs Change

GoodRx reported Q2 revenue of $200.4M, down 1%, and raised its full-year outlook, citing a projected 70% revenue increase from Pharma Direct. Oscar Health reported first-half 2026 results with revenue up 70% to $4.9B and record profitability, attributing gains to its AI platform and “Oswal” tools. Both cited shifting consumer insurance needs.

$GDRXHigh

GoodRx Holdings, Inc. (GDRX): Results of Operations and Financial Condition

GoodRx Holdings, Inc. (GDRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 gdrxq226-exx991pressrelease.htm EX-99.1 GDRX Q2'26 - EX-99.1 (Press Release) Exhibit 99.1 GOODRX REPORTS SECOND QUARTER 2026 RESULTS Pharma Direct and Subscription Revenue Increased 76% and 39% , Respectively, Year-Over-Year Company Raises Full-Year 2026 Revenue and Adj

$GDRXMed

GoodRx (GDRX) Stock Trades Up, Here Is Why

GoodRx (NASDAQ: GDRX) shares rose 2.6% after the company announced a partnership with Paytient to embed GoodRx’s prescription savings into employer-sponsored benefits. The integration is designed to offer lower cash prices at 70,000+ U.S. pharmacies. After the initial move, GDRX traded around $3.01, up 1.9%.

$GDRXMedAI 8/10

GoodRx Holdings, Inc. (GDRX) Strengthens Recurring Revenue Base with Companion

GoodRx (NASDAQ:GDRX) launched GoodRx Companion, a $14.99/month subscription aimed at patients with chronic conditions. The service offers savings on more than 200 generic medications and discounts on certain dental services, and it charges $19 for telehealth visits for common issues. The company said it is intended to strengthen its recurring revenue base beyond individual prescription transactions.